Category: ACCESSWIRE

Posted on

Global Partners for Development and 374Water Announce Partnership Project – The Homa Bay Blueprint: A Beacon for Climate Resilience in Africa

HOMA BAY, KENYA / ACCESSWIRE / January 23, 2024 / Global Partners for Development (GPFD) and 374Water, a global cleantech and social impact company, have announced plans for the Homa Bay Blueprint, a bold and comprehensive clean water initiative for Africa’s Great Lakes region. Both a live facility and a model for future replication, the project will feature cutting-edge wastewater treatment technology, an advanced data hub, and production of recycled resources. Located in Nam Lolwe (Lake Victoria), the continent’s largest lake by area, Homa Bay has seen farming and community pollution erode the health of its 1.3 million inhabitants and devastate ecology. Local preparations for the project have been completed by collaborators at the University of Nairobi, Kenya’s Ministry of Water and Environment, as well as Homa Bay government and community stakeholders.

Cutting-Edge Wastewater Treatment Technology

374Water’s AirSCWO technology, described as “a pressure cooker on steroids,” the AirSCWO process transforms any organic waste into minerals and clean water in seconds. It is the first and highly efficient technology to destroy hazardous PFAS, commonly known as “forever chemicals” associated with major health risks. Within three years, the Homa Bay Blueprint expects to improve the water quality of Lake Victoria by 20 percent.

Thus far, AirSCWO has been purchased by the Orange County Sanitation District in California and included in an environmental initiative by the Department of Defense. The Homa Bay Blueprint will be the technology’s first application in a developing nation, strategically executed by GPFD, an NGO with over 30 years of experience working with East African communities to implement health, education, and clean water programs.

“Developing nations, particularly Africa, are frequently offered lo-fi, unsustainable sanitation solutions that we wouldn’t use ourselves in the developed world. Instead, GPFD and 374Water are delivering extraordinarily advanced, long-lasting technology to solve the problems in Homa Bay and throughout the continent,” said Daniel Casanova, the Executive Director of GPFD.

Advanced Data Hub

The Homa Bay Blueprint will include a data hub powered by local scientists and researchers to collect, consolidate, analyze, and distribute the region’s most comprehensive information on lake water quality, empowering governments, community organizations, and locals to address pollution sources and monitor conditions for safer fishing, swimming, and water collection.

Recycled Resources and Building Economy

Through its water sanitation process, the AirSCWO system extracts minerals which the Homa Bay Blueprint will recycle and sell as fertilizer for farming. Heat expelled by the system will be used to dry seeds and fish on behalf of local businesses. Larger AirSCWO units planned for future projects also produce clean electricity. These renewable products represent profitable, new market opportunities for government and private industry.

To advance the local economy further, the Homa Bay Blueprint will be constructed by local workers using local materials and, long term, the facility will be led and run by trained local staff.

“The Homa Bay Blueprint, a partnership between GPFD, 374Water, and our local government is a genuine game-changer that will propel Homa Bay County onto the global stage,” said H. E. Gladys Nyasuna Wanga, Governor of Homa Bay County. “Issues related to environmental pollution and sewer management have long been considered life hazards. I am thrilled by the innovation that will transform the sanitation sector into a significant economic opportunity, leading Homa Bay into a circular economy and ultimately increasing the county’s income per capita. Homa Bay County warmly welcomes other stakeholders, nationally and internationally, to join us in setting a replicable precedent not only for Kenya but also across East Africa.”

The Blueprint

While the Homa Bay Blueprint will be a working facility exhibiting dedication to the goals of the Paris Agreement, COP28, and the inaugural 2023 Africa Climate Summit, the project will also serve as a model to be reproduced and scaled along the shores of Nam Lolwe, in East Africa, and throughout the continent. The way for replication will be paved by information from the data hub and by the very architecture of the AirSCWO system, which runs inside a 40-foot shipping container. Compared to the complex construction required of other sanitation systems, AirSCWO is a plug and play design that is simple for local communities to initiate and maintain.

“Through the Homa Bay Blueprint, we’re turning innovative technology into real-world solutions for climate and environmental challenges,” said Dr. Marc Deshusses, co-founder of 374Water. “This partnership with Global Partners for Development exemplifies our commitment to sustainable development and pollution control. It’s a model we hope to replicate across Africa, leading the way in environmental stewardship and community empowerment.”

About Global Partners for Development

Global Partners for Development, based in Petaluma, California, is a 45-year-old NGO that works in close partnership with local communities across East Africa to develop and implement sustainable solutions to the challenges they face. With a commitment to environmental stewardship and social entrepreneurship, we believe in harnessing the power of innovation to create a more equitable and sustainable future. To learn more visit gpfd.org.

About 374Water

374Water Inc. (NASDAQ:SCWO), a cleantech company, is leading innovation in waste and wastewater treatment, deploying advanced technology to transform challenges into sustainable solutions for both public and private sectors. 374Water’s AirSCWO technology spearheads a novel approach in waste treatment, epitomizing our dedication to technological excellence. As we navigate the pathway of a circular economy, our mission extends beyond mere solutions, aiming to redefine waste management standards. Follow us on LinkedIn.

For additional information, interviews, or to arrange a site visit, please contact:

Ria Pullin, Director of Marketing and Communications Global Partners for Development rpullin@gpfd.org  (707) 588-0550

SOURCE: Global Partners for Development

Posted on

IAVI and Zendal Announce Funding for Efficacy Trial of Promising TB VaccineCandidate in Africa

  • TB kills 1.3 million people a year and sickens more than 10 million people annually.
  • A new TB vaccine is needed to reach the global End TB goals.
  • MTBVAC is a highly promising vaccine candidate that has the potential to be used as an alternative to BCG vaccination in infants and for prevention of TB disease in adolescents and adults.
  • Grant from the Bill & Melinda Gates Foundation to IAVI will support efficacy trial.

NEW YORK, NY and PORRIÑO, SPAIN / ACCESSWIRE / December 18, 2023 / IAVI, a global nonprofit scientific research organization, and Spanish biopharmaceutical company Biofabri, a subsidiary of Zendal, today announced that the Bill & Melinda Gates Foundation has awarded IAVI US$55 million to conduct a Phase IIb trial assessing the safety and efficacy of the tuberculosis (TB) vaccine candidate MTBVAC to prevent active TB lung disease in adolescents and adults. This funding has been made possible in part through a grant provided by Open Philanthropy, a grant-making organization that aims to use its resources to help others as much as it can. This trial is also supported by additional funding provided by the German Federal Ministry of Education and Research (BMBF) through the KfW Development Bank, which provides funding to IAVI and partners in support of developing MTBVAC. It is anticipated that the trial will begin enrolling participants in mid-2024.

“We’re thrilled to have secured the investment needed to advance this promising vaccine candidate into an efficacy study,” said Mark Feinberg, M.D., Ph.D., president and CEO of IAVI. “The world urgently needs a new, effective vaccine that can prevent TB disease in adults and adolescents, and we are hopeful that MTBVAC will be part of the solution to finally end the TB epidemic. We are grateful to the Bill & Melinda Gates Foundation for their support of our late-stage development work on MTBVAC and to Open Philanthropy, whose visionary investment could accelerate the availability of MTBVAC by several years, if it is shown to be safe and efficacious in the upcoming efficacy trial.”

“This is a historic opportunity to learn whether this promising TB vaccine candidate, MTBVAC, can prevent active TB disease in adolescents and adults, the population among whom most TB disease and transmission occurs,” said Lewis Schrager, M.D., senior leader of TB vaccine development efforts at IAVI. “If MTBVAC were shown to safely prevent TB disease in this population, this vaccine could prove to be critically important in global strategies to suppress the TB pandemic given its ease of use, low cost, and anticipated widespread availability.”

Previous Phase Ib/IIa dose-ranging studies of MTBVAC in adults and neonates demonstrated favorable immunogenicity and safety profiles. In addition to this Phase IIb trial, Biofabri is conducting a Phase III trial of MTBVAC (NCT04975178) in neonates in South Africa, Madagascar, and Senegal, with support from the European & Developing Countries Clinical Trials Partnership (EDCTP). Biofabri and the HIV Vaccine Trials Network are planning a Phase IIa trial (NCT0547890) evaluating the safety and immunogenicity of MTBVAC in people living with HIV whose viral loads are well controlled on antiretroviral therapy, scheduled to begin in South Africa in mid-January 2024.

Only a handful of TB vaccine candidate efficacy trials have ever been conducted. This study of MTBVAC to prevent TB disease will be conducted in approximately 4,300 people who have latent TB infection. Participants will be between the ages of 14 and 45, living in South Africa and select other sub-Saharan African countries in areas with high TB burden. Participants at 15-20 trial sites will receive either a single dose of MTBVAC or placebo and be observed for two to three years.

Kundai Chinyenze, M.D., MPH, IAVI Africa director, said, “We are gratified to be able to begin working on this efficacy trial in a region of the world where TB is a leading contributor to morbidity and mortality, especially for people living with HIV. IAVI’s long history in conducting clinical trials in Africa and our strong network of regional and global partners provide a solid foundation for the successful conduct of this important trial.”

MTBVAC, designed by the Spanish researcher Carlos Martin, Ph.D., from the University of Zaragoza, and Brigitte Gicquel, Ph.D., of Institut Pasteur, was in-licensed by Biofabri (Zendal Group). The only available TB vaccine, bacille Calmette-Guérin (BCG), is derived from Mycobacterium bovis, a bacterium that causes a TB-like disease in cows. BCG is largely ineffective in preventing TB in adolescents and adults. MTBVAC is the only live, attenuated vaccine derived from Mycobacterium tuberculosis, the bacterium that causes TB disease in humans, in the pipeline. Given its derivation from the human, rather than the bovine, TB-causing organism, MTBVAC has the potential to generate a broad protective immune response against TB. The vaccine is administered as a single dose via intradermal delivery and does not require the use of an adjuvant.

Esteban Rodriguez, CEO, Biofabri, said, “We are delighted by the fantastic opportunity – through the tremendous efforts of IAVI, and the valuable support provided by the Bill & Melinda Gates Foundation, Open Philanthropy, and the German Federal Ministry of Education and Research (BMBF) through the KfW Development Bank – to now evaluate the efficacy of MTBVAC in adolescents and adults. The outcome of the efficacy studies in neonates as well as those in adolescents and adults will provide us with a pathway to license MTBVAC for all age groups.”

Should MTBVAC be shown to be safe and efficacious, Biofabri, in partnership with IAVI and other collaborators, will ensure that MTBVAC is manufactured and supplied in sufficient quantities globally and is accessible at affordable prices in low- and middle-income countries.

TB

Since the COVID-19 emergency has ended, TB is on track once again to be the deadliest infectious disease in the world. TB killed an estimated 1.3 million people in 2022, about 16% of whom were children. Around 10.6 million people fell ill with TB in 2022, and the disease is one of the 10 leading causes of death worldwide.

Drug-resistant/multi-drug resistant TB (DR/MDR TB) is becoming an increasing threat, with about 410,000 cases in 2022. Treating DR/MDR TB is lengthy and expensive, often causes debilitating side effects, and is not always successful. A vaccine that prevents TB disease would play an important role in reducing the incidence of DR/MDR TB, by reducing the transmission of DR/MDR TB and reducing the use of TB drugs and the emergence of drug-resistant strains.

MTBVAC

MTBVAC is being developed for two purposes: as a more effective and potentially longer-lasting vaccine than BCG for newborns, and for the prevention of TB disease in adults and adolescents, for whom there is currently no effective vaccine.

Two Phase II trials have been completed, one supported by EDCTP and sponsored by Biofabri in infants in South Africa, and one sponsored by IAVI and supported by the U.S. National Institutes of Health and the U.S. Department of Defense through its Congressionally Directed Medical Research Program. Results are expected to be published in early 2024.

IAVI. IAVI is a nonprofit scientific research organization with headquarters in the U.S. and locations in Europe, Africa, and India that develops vaccines and antibodies for HIV, tuberculosis, emerging infectious diseases (including COVID-19), and neglected diseases, with the goal of providing global access. It has contributed to efforts to evaluate most of the leading TB vaccine candidates now in clinical development and has a highly experienced TB vaccine clinical research team in South Africa.

Biofabri. Biofabri is a biopharmaceutical company created in 2008 with the aim of researching, developing, and manufacturing vaccines for humans. Biofabri has a solid technical and scientific capacity in vaccines and immunotherapy. Biofabri belongs to the Zendal group, a Spanish pharmaceutical business group made up of six companies specialised in the development, manufacture and marketing of vaccines and other biotechnological products for human and animal health.

UNIZAR. The University of Zaragoza in Spain is the main center for technological innovation in the Ebro Valley. It participates in different exchange programs, collaborating with universities and research centers in Europe, Latin America, and the United States. Microbiologists from the university associated with Centro de Investigación Biomédica en Red Enfermadades Respiratorias (CIBERES) led the research and subsequent discovery of the experimental vaccine MTBVAC. Within the TuBerculosis Vaccine Initiative (TBVI) consortium, the MTBVAC discovery phase has included rigorous clinical characterization by independent laboratories and research groups.

IAVI Media Contact

Karie Youngdahl
+1 212 847 1051
kyoungdahl@iavi.org

Zendal Media Contact
Beatriz Díaz Lorenzo
+34 619 085 074
b.diaz@zendal.com

SOURCE: IAVI

Posted on

LBank Announces a Blockbuster Roadshow to Facilitate Web3 and Crypto Adoption

DUBAI, UAE / ACCESSWIRE / June 28, 2023 / LBank, a global digital asset trading platform, is set to embark on an exciting educational initiative to enhance cryptocurrency awareness in key regions worldwide. The ‘LBank Roadshow,’ a series of events, will be held in seven major cities, spanning June to August. As part of the broader LBank events, the LBank Roadshow focuses explicitly on fostering the development of the thriving blockchain and crypto ecosystems in India, Seoul, Bangkok, Manila, Dubai, Kuala Lumpur, Istanbul, and Tokyo. By empowering and inspiring younger generations to embrace Web3 and leverage crypto tools, this initiative seeks to propel the adoption and understanding of these transformative technologies.

Innovation serves as a fundamental driving force for any team or projects striving to maintain a competitive edge, particularly in the realm of Web3. Its significance cannot be underestimated. However, even with seminal ideas, their potential can remain unrealized if they aren’t shared with the appropriate audience. This is precisely where LBank steps in. Introducing the LBank Roadshow, a collection of complimentary one-day events designed to provide traders, crypto enthusiasts, developers, and builders worldwide with workshops and panel discussions. The Roadshow presents an exceptional opportunity to acquire fresh Web3 skills, gain visibility, forge valuable connections, and propel your innovative ventures to new heights.

LBank recognizes the vital role played by crypto enthusiasts in nurturing the web3 ecosystem. To cater to their needs and provide an enriching experience, we have curated a remarkable series of events. Immerse yourself in a range of captivating activities, such as enlightening educational sessions, stimulating panel discussions, captivating keynote speeches, and invaluable networking opportunities with fellow passionate individuals who share your interests.

LBank CEO, Allen Wei said, “We are committed to empowering the growth and prosperity of our listed projects, and our roadshow events provide an ideal platform to enhance their market impact. These events offer a unique opportunity for attendees to engage with potential investors, developers, partners, and users while immersing themselves in the thriving crypto communities of these cities.”

He further stated: “As we establish our global presence through the ‘Web3 Connect’ Roadshow events, we strive to lead the way in driving positive change within the crypto world.”

Registrations for the Roadshow will be strictly curated so that we assemble high-quality cohorts at each event. Registration also comes with an amazing affiliate program and promotional offers.

Promotional Offers
To expand its influence and gain more substantial support from the cryptocurrency community, LBank is introducing enticing incentives for traders on its platform. Users now have the chance to earn bonuses while also being invited to participate in an enriching affiliate program.

As a gesture of goodwill, LBank is granting new users the exclusive privilege of testing the platform with a live account that comes pre-funded with a registration bonus. Adding to the excitement, all new users will also receive a daily trading bonus. To claim this bonus, new users simply need to follow us.

Through LBank’s Affiliate Program, users have the potential to earn impressive commissions of up to 50% from direct traffic, including Maker Fees payments. Additionally, indirect traffic generated through sub-affiliates offers an extra 20% in commissions. This presents a remarkable opportunity for cryptocurrency enthusiasts to capitalize on one of the most outstanding affiliate programs available in the industry, enabling them to potentially earn a substantial income.

Community & Social Media: Telegram l Twitter l Facebook l Linkedin

Contact Details:

Abhinav Mehta
LBK Blockchain Co. Limited
media@lbank.info

SOURCE: LBank

Posted on

IAVI Starts First-in-Human Phase I Clinical Trial of Single-Dose Sudan Virus Vaccine Candidate

NEW YORK, NY / ACCESSWIRE / June 27, 2023 / IAVI announced today that the first participants have been vaccinated with a Sudan virus (SUDV) vaccine candidate in a first-in-human Phase I clinical trial in the U.S. The IAVI-sponsored trial is funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).

Known as IAVI C108, this first-in-human study is designed to evaluate the safety and immunogenicity of an investigational SUDV vaccine candidate donated to IAVI by Merck (known as MSD outside the U.S. and Canada) to supplement IAVI’s ongoing SUDV vaccine development program. This investigational SUDV vaccine candidate was produced for IAVI from existing investigational bulk drug substance previously manufactured by Merck. IAVI is the vaccine candidate’s regulatory sponsor. IAVI is responsible for all aspects of the candidate’s future development, including demonstrating equivalence between this SUDV vaccine candidate and IAVI’s other SUDV vaccine candidate, which utilizes the same viral vector but is manufactured using a new production platform.

The SUDV vaccine candidate being evaluated in IAVI C108 uses the same recombinant vesicular stomatitis virus (rVSV) viral vector platform as ERVEBO®, Merck’s single-dose Zaire ebolavirus (ZEBOV) vaccine which is licensed in the U.S., U.K., European Union, Canada, Switzerland, and 10 African countries. rVSV is also the platform technology utilized in IAVI’s portfolio of emerging infectious disease (EID) candidates.

“IAVI C108 represents an important first step toward generating the data needed for eventual licensure of an rVSV-SUDV vaccine. The development and licensure of ERVEBO® has resulted in an important tool in Ebola Zaire outbreak response. If proven effective, we’re hopeful that a vaccine candidate built on the same viral platform will be similarly important in future SUDV outbreaks,” said Swati Gupta, Ph.D., vice president and head of emerging infectious diseases and epidemiology at IAVI. “In parallel, we must continue accelerating efforts toward the adequate availability of candidate vaccine doses for evaluation during and ahead of outbreaks with key partners, collaborators, and funders. We’re grateful to Merck for donating the doses that will be used in IAVI C108 and to BARDA for its support of this trial.”

IAVI C108 will take place at two U.S.-based clinical trial sites, where the study vaccine will be administered intramuscularly at three dosage levels. This is a placebo-controlled, single-blind study, meaning that only the researchers conducting the study will know whether a participant has received a vaccine dose or a placebo dose until after the trial is over. Approximately 36 healthy adults will be enrolled and will be followed for six months after vaccination to monitor their safety and immune responses to the vaccine candidate.

Like ZEBOV, SUDV is responsible for recurring viral hemorrhagic fever outbreaks, which have had lasting impacts on health security and geopolitical stability across sub-Saharan Africa. The estimated case fatality ratios of SUDV disease have varied from 41% to 100% in past outbreaks[1]. Despite high morbidity and mortality, there are no vaccines or therapeutics licensed for the prevention and treatment of SUDV. Existing ZEBOV vaccines and treatments are not effective against SUDV. Data being generated from ongoing studies suggest that rVSV could be a safe and effective platform for responding to SUDV and other related pathogens[2].

IAVI’s rVSV-based EID portfolio includes a SUDV vaccine candidate supported by BARDA; a Lassa fever virus vaccine candidate currently in a Phase I trial and supported by the Coalition for Epidemic Preparedness Innovations and the European & Developing Countries Clinical Trials Partnership; a Marburg virus vaccine candidate supported by BARDA and the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DOD); and an intranasal SARS-CoV-2 vaccine candidate supported by DOD DTRA and the Japan Ministry of Finance.

The rVSV platform has been used extensively in adults and children[3]. The underlying vesicular stomatitis virus (VSV) is a common animal virus that does not cause serious illness in humans and has been investigated extensively as a vaccine vector. In the vaccine platform, it is engineered to encode a surface protein from a target pathogen – in this case, SUDV – to prompt the body to mount an immune response.

Much of the research and development on IAVI’s rVSV platform is performed at the IAVI Vaccine Design and Development Lab (DDL) in Brooklyn, New York. The DDL is located at the bioscience center in the historic Brooklyn Army Terminal. Since its founding in 2008, the IAVI DDL has become one of the world’s leading viral vector vaccine research and development labs, known for innovation and generation of novel vaccine design concepts.

Scientists with IAVI’s Human Immunology Laboratory (HIL) in London, U.K., are involved in processing participant samples and developing the analytical assays needed to evaluate IAVI C108 participants’ immune responses. Established in 2001, the HIL is fully integrated into the Infectious Disease department within the Faculty of Medicine at Imperial College London and serves as the clinical immunology reference laboratory for IAVI and the network of clinical research centers with which IAVI collaborates worldwide.

Media Contact
Rose Catlos
Rcatlos@iavi.org
212-847-1049

About IAVI
IAVI is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV, tuberculosis, and emerging infectious diseases. Its mission is to translate scientific discoveries into affordable, globally accessible public health solutions. Read more at iavi.org.

Follow IAVI on Facebook, LinkedIn, Instagram, and YouTube, and subscribe to our news updates.

About IAVI’s rVSV vaccine candidates
IAVI holds a nonexclusive license to the rVSV vaccine candidates from the Public Health Agency of Canada (PHAC). The vector was developed by scientists at PHAC’s National Microbiology Laboratory.

IAVI initially developed its rVSV vector for HIV vaccine candidates and has since expanded its use to the development of vaccines addressing emerging infectious diseases (Lassa Fever, Marburg, Sudan ebolavirus, and COVID-19).

Funders who have made the development of IAVI’s rVSV-vectored vaccine candidates possible include the Bill & Melinda Gates Foundation; the Government of Canada; the Danish Ministry of Foreign Affairs; the Government of Japan; the Irish Department of Foreign Affairs and Trade; the Netherlands Ministry of Foreign Affairs; the Norwegian Agency for Development Cooperation; the U.K Department for International Development; the U.S. National Institutes of Health; and through the generous support of the American people from the United States Agency for International Development.

This project is funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority under contract number 75A50121C00077.

[1] https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON410

[2] https://link.springer.com/article/10.1007/s11262-017-1455-x

[3] https://cdn.who.int/media/docs/default-source/blue-print/who-vaccine-prioritization-report-uganda-ebola-trial-nov-16-2022.pdf

SOURCE: IAVI

Posted on

South Africa’s “Oasis (Reach for Your Dreams)” Receives Recognition from UNAOC-BMW Group’s Intercultural Innovation Hub

BERLIN, GERMANY / ACCESSWIRE / May 25, 2023 / South African organization “Oasis: `Reach For Your Dreams`” is one of ten global grassroots recognized by the prestigious Intercultural Innovation Hub, a joint initiative of the United Nations Alliance of Civilizations (UNAOC) and the BMW Group, implemented with the support of Accenture, during a ceremony held in Berlin, Germany.

Selected for their project “Community Street Football/Netball”, the organization leverages the role of sport to help youth who have fallen through the gaps within society, and have either dropped out of school or have become involved in gang-related activities, by supporting their reintegration into society and empowering them to lead positive and self-sufficient lives. The programme engages participants in street football events, while uplifting young people by instilling them with life skills based on the values inherent to sports, such as team spirit, fair play, respect, and conflict management.

“We are honored to receive the support of the Intercultural Innovation Hub in addressing the challenges of the youth in our communities, and providing alternative solutions for their positive growth,” said Clifford Martinus, Founder of “Oasis `Reach For Your Dreams`”.

Every year, the Intercultural Innovation Hub supports grassroots initiatives that promote intercultural dialogue and understanding, thereby contributing to peace, cultural diversity, and more inclusive societies. This year, the Ceremony was chaired by Mr. Miguel Ángel Moratinos, United Nations Under-Secretary-General and the High Representative for UNAOC, and Ms. Ilka Horstmeier, Member of the Board of Management of BMW AG People and Real Estate, Labour Relations Director.

Through the Intercultural Innovation Hub, Oasis `Reach For Your Dreams` will receive a financial grant, as well as one year of capacity-building and mentorship support from UNAOC, the BMW Group, and Accenture to help strengthen the “Community Street Football/Netball” project and its contribution towards a more inclusive society. This model of collaboration between the United Nations and the private sector creates a more profound impact, as partners provide their respective expertise to ensure the sustainable growth of each supported project.

Learn more about the project:

https://interculturalinnovation.org/oasis-reach-for-your-dreams-community-street-football-netball/

Media Inquiries:

– Milena Pighi, Head of Corporate Social Responsibility, BMW Group, Milena.PA.Pighi@bmw.de
– Alessandro Girola, Programming Coordinator, UNAOC, alessandrog@unops.org

SOURCE: United Nations Alliance of Civilizations (UNAOC)

Posted on

Encryptus Unveils the Largest Payout Network at Coindesk Consensus

LITHUANIA, EUROPE / ACCESSWIRE / May 8, 2023 / Encryptus, a leading cryptocurrency solutions provider, announced during Coindesk’s Consensus event the launch of industry leading payout product, which allows crypto exchanges, wallet providers, Web3, Gaming and other B2C crypto companies to off-ramp to Bank Wires, Mobile Wallets, Mobile Top-ups and Gift Cards with API’s.The payout network has coverage in 79 Countries for Bank Wires in 41 currencies, 39 countries for Mobile Wallets and 115+ countries for mobile top ups and gift cards. There are over 7,500 different types of gift cards and prepaid airtime of 307 Mobile operators globally available with Encryptus’s payouts. Popular Mobile Wallets like AliPay, GoCash and M-Pesa are among the few available.

As part of its commitment to regulatory compliance, Encryptus does not provide off ramps to sanctioned countries and clients. In addition the services are not available to residents and citizens of the US, Canada and Japan due to the regulatory landscape. The payout product is particularly beneficial for users looking to cash out crypto to fiat (national currencies) to their own bank accounts or purchase gift cards or mobile plans in over 100 countries. The payouts combined will be available in 98 currencies. The services are available via APIs but the company will unveil their widget soon.

Encryptus’ payout product is fully automated, with compliance monitoring tools to identify PEP and Sanctioned users and dirty coins via coin monitoring being integrated into its APIs.

“We are excited to launch our payouts; QuickRemit. Our payout network is not just the largest but offers the widest form of payments in the crypto industry. The API offers payout as a service and also keeps compliance as a core offering. Our vision is to further expand our payout coverage with a commitment to reduce the costs of payouts for the users” said Shantnoo Saxsena, CEO of Encryptus.

Shantnoo further explained that true crypto adoption will not happen with good pay-in networks, but with an extension to multiple payouts. Exchanges and crypto companies must not just focus on bringing users to their platform, but they must offer their users enough freedom to cash out.

Encryptus has aggressively priced the global bank wires for a flat fee of 1.5% and have a revenue share reserve from this amount for their partners. The accepted crypto would only be USDT and USDC.

The company promises to simplify global mobile wallet payouts and business payments in the upcoming upgrade.

Overall, the launch of the new payout product by Encryptus represents a significant milestone in the evolution of blockchain-based payments solutions. The need of the hour is to provide a secure, automated, and affordable way to off-ramp crypto holdings into various forms of payments. Encryptus is helping to further expand the adoption of cryptocurrencies and drive innovation in the fintech industry.

Twitter: https://twitter.com/EncryptusGlobal
LinkedIn: https://www.linkedin.com/company/encryptus/
Website: https://encryptus.io/

Please free to contact Abhi@encryptus.io for any queries.

SOURCE: Encryptus

Posted on

LBank to Participate in the Inaugural Web3 Festival in Hong Kong

DUBAI, UAE / ACCESSWIRE / April 15, 2023 / LBank, a top cryptocurrency exchange, is proud to announce its participation in the inaugural Web3 Festival taking place from April 12-15 at the Hong Kong Convention and Exhibition Centre (HKCEC). The festival is co-hosted by Wanxiang Blockchain Labs and HashKey Group and organized by W3ME.The event promises to be an exciting four-day gathering of thousands of attendees, featuring hundreds of distinguished industry speakers, Web3 projects, community partners and media partners from around the world. With five center stages spread across an area of about 9,000㎡, the festival will provide a unique opportunity for attendees to network, share, and learn through high-level content and panel discussions.

At the Web3 Festival, LBank will have the opportunity to showcase its innovative cryptocurrency trading platform and engage with industry leaders and participants. The festival aims to bring together the world’s brightest minds, top Web3 projects and leading venture capitals, presenting content-rich discussions and topics centered around Web3. The festival will also feature regulatory representatives from Hong Kong who will dive into and interpret the latest digital asset regulation policies.

In addition, attendees should get ready for an evening of unforgettable experiences as LBank presents the AfterParty, called LBank Friday Crypto Vibes, in Hong Kong on April 14th from 6 to 10 PM HKT. The event, which will be held at 64 Jaffe Road, promises live music, scrumptious food, and unlimited drinks. LBank is proud to collaborate with LBank Labs and Encryptus as sponsors for the occasion. This is the perfect opportunity for attendees to connect with crypto-native leaders, operators, builders, institutions, and investors from the most innovative and creative organizations in the ecosystem.

Overall, LBank is excited to participate in this global gathering of Web3 professionals, and looks forward to joining discussions aimed at advancing the development and adoption of Web3 technologies. As a leader in the cryptocurrency exchange industry, LBank is committed to exploring new opportunities and partnerships that will benefit the entire blockchain ecosystem.

About LBank

LBank is a global top cryptocurrency exchange founded in 2015 for buying, selling, receiving and storing Bitcoin and other digital currencies. It provides its 9 million+ users with a secure trading platform and the lowest transaction fees.

The platform supports more than 800 trading pairs and 149+ fiat currencies. It offers services around crypto trading, specialized financial derivatives, and professional asset management services.

Start Trading Now: Ibank.com

Community & Social Media:

lTelegram

lTwitter

lFacebook

lLinkedin

Contact Details:

LBK Blockchain Co. Limited
press@lbank.info

SOURCE: LBank